Pravastatin

Generic Name: Pravastatin

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₃₆O_₇

CAS Number: 81093-37-0

Unique Ingredient Identifier: KXO2KT9N0G

Background: Pravastatin is the 6-alpha-hydroxy acid form of mevastatin. Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. It was the first statin administered as the active form and not as a prodrug. This drug was developed by Sankyo Co. Ltd.; however, the first approved pravastatin product was developed by Bristol Myers...

Indication: Pravastatin is indicated for primary prevention of coronary events hypercholesterolemic patients without clinical evidence of coronary heart disease. Its use includes the reduction of risk on myocardial infarction, undergoing myocardial revascularization procedures and cardiovascular mortality.
...

Associated Conditions: Acute Coronary Events, Cardiovascular Outcomes, Coronary Artery Atherosclerosis, Death, Dysbetalipoproteinemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Hyperlipidemias, Mixed Dyslipidemias, Myocardial Infarction, Myocardial Revascularization, Secondary prevention cardiovascular event, Stroke, Sudden Cardiac Death, Transient Ischemic Attack, Elevation of serum triglyceride levels

Associated Therapies: -

Clinical Trials

Bioavailability Study of Pravastatin Sodium 40 mg Tablets Under Fasting Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pravachol®
Drug: pravastatin sodium

First Posted Date: 2009-02-03

Last Posted Date: 2020-10-08

Lead Sponsor: Teva Pharmaceuticals USA

Target Recruit Count: 58

Registration Number: NCT00834379

Locations: 🇨🇦
Pharma Medica Research Inc., Toronto, Ontario, Canada

Pravastatin Sodium 40 mg Tablets Food Challenge Study

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pravachol®
Drug: pravastatin

First Posted Date: 2009-02-03

Last Posted Date: 2020-01-09

Lead Sponsor: Teva Pharmaceuticals USA

Target Recruit Count: 24

Registration Number: NCT00834847

Locations: 🇨🇦
Pharma Medica Research Inc., Toronto, Ontario, Canada

Pravastatin 80 mg Tablets Dosed in Healthy Subjects Under Non-Fasting Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pravastatin

First Posted Date: 2009-01-27

Last Posted Date: 2024-08-20

Lead Sponsor: Teva Pharmaceuticals USA

Target Recruit Count: 16

Registration Number: NCT00829309

Locations: 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States

Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients (MK0653A-168)

Phase 3

Terminated

Conditions: Hypertension

Interventions: Drug: valsartan
Drug: pravastatin
Drug: ezetimibe (+) simvastatin
Drug: simvastatin

First Posted Date: 2008-08-21

Last Posted Date: 2013-08-26

Lead Sponsor: Fundación Lindavista del Corazón AC

Target Recruit Count: 12

Registration Number: NCT00738972

Vytorin on Carotid Intima-media Thickness and Overall Rigidity

Phase 4

Completed

Conditions: Cardiovascular Diseases

Interventions: Drug: ezetimibe (+) simvastatin
Drug: pravastatin
Drug: simvastatin

First Posted Date: 2008-08-20

Last Posted Date: 2015-06-24

Lead Sponsor: Hospital Universitario 12 de Octubre

Target Recruit Count: 90

Registration Number: NCT00738296

Pravastatin and Ventilatory Associated Pneumonia

Early Phase 1

Completed

Conditions: Ventilator Associated Pneumonia

Interventions: Drug: Pravastatin

First Posted Date: 2008-06-20

Last Posted Date: 2011-11-30

Lead Sponsor: University of Thessaly

Target Recruit Count: 152

Registration Number: NCT00702130

Locations: 🇬🇷
General Hospital Larissa, Larissa, Thessalia, Greece
🇬🇷
Zakynthinos E. Dir-University Hospital Larisa, Mezourlo / Larissa, Greece

South Korean Pitavastatin Heart Failure Study

Phase 4

Completed

Conditions: Chronic Heart Failure

Interventions: Drug: pitavastatin
Drug: pravastatin

First Posted Date: 2008-06-19

Last Posted Date: 2014-05-14

Lead Sponsor: JW Pharmaceutical

Target Recruit Count: 70

Registration Number: NCT00701285

Locations: 🇰🇷
SEOUL St. Mary's Hospital, Seoul, Seocho-Ku, Korea, Republic of

A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)

Phase 2

Completed

Conditions: Dyslipidemia

Interventions: Drug: Placebo
Drug: Pravastatin
Drug: Dalcetrapib

First Posted Date: 2008-06-13

Last Posted Date: 2020-01-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 292

Registration Number: NCT00697203

Pravastatin for Acute Myocardial Infarction With Minimally to Mildly Increased Levels of Serum Cholesterol Study

Phase 4

Conditions: Acute Myocardial Infarction

First Posted Date: 2008-06-03

Last Posted Date: 2008-12-02

Lead Sponsor: Osaka Acute Coronary Insufficiency Study Group

Target Recruit Count: 400

Registration Number: NCT00688922

Locations: 🇯🇵
Higashi-Osaka City General Hospital, Higashi-Osaka, Osaka, Japan
🇯🇵
Kawachi General Hospital, Higashi-Osaka, Osaka, Japan
🇯🇵
Kansai Rosai Hospital, Amagasaki, Hyogo, Japan

and more 6 locations

The Influence of Raltegravir on Pravastatin Pharmacokinetics(GRAPPA)

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Pravastatin and raltegravir
Drug: Pravastatin
Drug: Raltegravir

First Posted Date: 2008-04-24

Last Posted Date: 2020-10-19

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 24

Registration Number: NCT00665717

Locations: 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy